Drug intelligence / Profile preview

AMP-Bio

Development stage: Preclinical
Lead developer: BIO-XL
Modality: Peptides

Overview

AMP-Bio is an antimicrobial peptide (AMP) therapy being developed by BIO-XL for the treatment of antibiotic-resistant bacterial infections. The program focuses on engineering peptides that can effectively kill or neutralize bacterial pathogens, including those resistant to conventional antibiotics, while minimizing disruption to the host's commensal microbiome. It is currently in the discovery and preclinical stages of development.

Beyond the preview

Go deeper on AMP-Bio.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMP-Bio.

Explore the full profile